New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving treatment ...
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...
GSK analysis shows Seretide/Advair is a well tolerated and effective medicine for controlling asthma
London UK - The U.S. Food and Drug Administration today posted a comprehensive review conducted by GlaxoSmithKline of its clinical and observational data that demonstrated better overall asthma ...
Results of the European INSPIRE (Investigating New Standards for Prophylaxis in Reduction of Exacerbations) study, published in the American Journal of Respiratory and Critical Care Medicine (2008: ...
GlaxoSmithKline has received approval in Japan for its key respiratory product Seretide/Advair Diskus and its anti-thrombotic Arixtra, a move which the company says should make a significant ...
GlaxoSmithKline (GSK) today announced that it has received approval for Seretide/Advair Diskus (salmeterol and fluticasone proprionate combination) and Arixtra (fondaparinux sodium) from the Ministry ...
Lagos — GLAXOSMITHKLINE Pharmaceutical Nigeria Plc (GSK), one of the leading pharmaceutical companies would today launch its anti-asthmatic drug seretide diskus, in the country. According to a ...
Seretide diskus, a combination inhaler and the world's biggest selling anti-asthmatic medication from the stable of GlaxoSmithkline Pharmaceutical Nigeria PLC (GSK), is set to be launched into the ...
This study has demonstrated that doubling the dose of Seretide™ administered via the Diskus™ inhaler over a short period is safe and well tolerated. Whilst this is not a recommended treatment approach ...
GlaxoSmithKline plc (GSK) and biopharmaceutical company Theravance, Inc. announced positive results from three phase III studies. Two studies comparing the efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results